Literature DB >> 15852247

TNF pathophysiology in murine models of chronic inflammation and autoimmunity.

George Kollias1.   

Abstract

Experimental work in animal models is providing important clues on the specific function of tumor necrosis factor (TNF) and its receptors in disease, especially on the molecular and cellular pathways through which TNF mediates beneficial and deleterious responses. Emerging data on the posttranscriptional regulatory processes, secretion, and postreceptor actions of TNF indicate a variety of mechanisms that may be causative of disease. More recent evidence in murine disease models has indicated heterogeneity of TNF receptor usage in autoimmune disease suppression versus inflammatory tissue damage, suggesting that selective TNF receptor inhibition may be advantageous to anti-TNF treatments in combating chronic inflammatory disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15852247     DOI: 10.1016/j.semarthrit.2005.01.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  30 in total

1.  Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies.

Authors:  Yukihiro Takemura; Noriyuki Ouchi; Rei Shibata; Tamar Aprahamian; Michael T Kirber; Ross S Summer; Shinji Kihara; Kenneth Walsh
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

2.  Dual role for RhoA in suppression and induction of cytokines in the human neutrophil.

Authors:  Michael B Fessler; Patrick G Arndt; Ingo Just; Jerry A Nick; Kenneth C Malcolm; G Scott Worthen
Journal:  Blood       Date:  2006-10-03       Impact factor: 22.113

3.  Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration.

Authors:  Yun Dong; Roman Fischer; Petrus J W Naudé; Olaf Maier; Csaba Nyakas; Maëlle Duffey; Eddy A Van der Zee; Doortje Dekens; Wanda Douwenga; Andreas Herrmann; Eric Guenzi; Roland E Kontermann; Klaus Pfizenmaier; Ulrich L M Eisel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-10       Impact factor: 11.205

4.  TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.

Authors:  Thomas Calzascia; Marc Pellegrini; Håkan Hall; Laurent Sabbagh; Nobuyuki Ono; Alisha R Elford; Tak W Mak; Pamela S Ohashi
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 5.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

6.  TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells.

Authors:  Haishan Li; Kun Luo; C David Pauza
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

7.  TNFalpha shedding and epidermal inflammation are controlled by Jun proteins.

Authors:  Juan Guinea-Viniegra; Rainer Zenz; Harald Scheuch; Denes Hnisz; Martin Holcmann; Latifa Bakiri; Helia B Schonthaler; Maria Sibilia; Erwin F Wagner
Journal:  Genes Dev       Date:  2009-11-15       Impact factor: 11.361

8.  NF-κB RNAi decreases the Bax/Bcl-2 ratio and inhibits TNF-α-induced apoptosis in human alveolar epithelial cells.

Authors:  Li Li; Weijing Wu; Wenjie Huang; Gen Hu; Weifeng Yuan; Weifeng Li
Journal:  Inflamm Res       Date:  2013-01-20       Impact factor: 4.575

9.  Mast cells are an essential hematopoietic component for polyp development.

Authors:  Elias Gounaris; Susan E Erdman; Clifford Restaino; Michael F Gurish; Daniel S Friend; Fotini Gounari; David M Lee; Guoying Zhang; Jonathan N Glickman; Kichul Shin; Varada P Rao; Theofilos Poutahidis; Ralph Weissleder; Kelly M McNagny; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

Review 10.  Use of the tumor necrosis factor-blockers for Crohn's disease.

Authors:  Alan B R Thomson; Milli Gupta; Hugh J Freeman
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.